Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.57 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505307 | 0.87 | GRM5 (0.57) | GRM5BCL6HTTNR1I2AHR | |
| SCHEMBL4518773 | 0.81 | GRM5 (0.61) | GRM5BCL6MEN1KMT2AKDR | |
| SCHEMBL3632867 | 0.78 | KDR (0.54) | GRM5MEN1KMT2AHSD17B10MET | |
| SCHEMBL4511277 | 0.77 | GRM5 (0.50) | GRM5BCL6 | |
| SCHEMBL4517050 | 0.77 | GRM5 (0.54) | GRM5BCL6HTT | |
| SCHEMBL27801687 | 0.76 | NPC1 (0.48) | GRM5MEN1KMT2AHSD17B10MET | |
| SCHEMBL3633502 | 0.76 | GRM5 (0.47) | GRM5MEN1KMT2AHSD17B10MET | |
| SCHEMBL4508452 | 0.74 | GRM5 (0.50) | GRM5BCL6LRRK2MEN1HTT | |
| SCHEMBL23758268 | 0.73 | MAPK1 (0.54) | MEN1KMT2AHSD17B10 | |
| SCHEMBL4505177 | 0.72 | GRM5 (1.00) | GRM5BCL6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| CN-101460478-A | Novel bi-aryl amines | NOVARTIS AG (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2004624-A1 | NOVEL BI-ARYL AMINES | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NAT1, MAOB, CYP2B6 | GRM5 3095/4885BCL6 2305/4885LRRK2 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.